Literature DB >> 11205147

Changes in cytokines and neurotrophins in Parkinson's disease.

T Nagatsu1, M Mogi, H Ichinose, A Togari.   

Abstract

Degeneration of the dopamine (DA) neurons of the substantia nigra pars compacta and the resulting loss of nerve terminals accompanied by DA deficiency in the striatum are responsible for most of the movement disturbances called parkinsonism, observed in Parkinson's disease (PD). One hypothesis of the cause of degeneration of the nigrostriatal DA neurons is that PD is caused by programmed cell death (apoptosis) due to increased levels of cytokines and/or decreased ones of neurotrophins. We and other workers found markedly increased levels of cytokines, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-2, IL-4, IL-6, transforming growth factor (TFG)-alpha, TGF-beta1, and TGF-beta2, and decreased ones of neurotrophins, such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), in the nigrostriatal DA regions and ventricular and lumbar cerebrospinal fluid of PD patients. Furthermore, the levels of TNF-alpha receptor R1 (TNF-R1, p55), bcl-2, soluble Fas (sFas), and the activities of caspase-1 and caspase-3 were also elevated in the nigrostriatal DA regions in PD. In experimental animal models of PD, IL-1beta level was increased and NGF one decreased in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonian mice, and TNF-alpha level was increased in the substantia nigra and striatum of the 6-hydroxydopamine (6OHDA)-injected side of hemiparkinsonian rats. L-DOPA alone or together with 6OHDA does not increase the level of TNF-alpha in the brain in vivo. Increased levels of proinflammatory cytokines, cytokine receptors and caspase activities, and reduced levels of neurotrophins in the nigrostriatal region in PD patients, and in MPTP- and 6OHDA-produced parkinsonian animals suggest increased immune reactivity and programmed cell death (apoptosis) of neuronal and/or glial cells. These data indicate the presence of such proapoptotic environment in the substantia nigra in PD that may induce increased vulnerability of neuronal or glial cells towards a variety of neurotoxic factors. The probable causative linkage among the increased levels of proinflammatory cytokines and the decreased levels of neurotrophins, candidate parkinsonism-producing neurotoxins such as isoquinoline neurotoxins (Review; Nagatsu, 1997), and the genetic susceptibility to toxic factors, remains for further investigation in the molecular mechanism of PD. The increased cytokine levels, decreased neurotrophin ones, and the possible immune response in the nigrostriatal region in PD indicate new neuroprotective therapy including nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, immunosuppressive or immunophilin-binding drugs such as FK-506, and drugs increasing neurotrophins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11205147     DOI: 10.1007/978-3-7091-6301-6_19

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  147 in total

1.  Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson's disease.

Authors:  Annadurai Anandhan; Musthafa Mohamed Essa; Thamilarasan Manivasagam
Journal:  Neurotox Res       Date:  2012-06-06       Impact factor: 3.911

2.  Testing NF-κB-based therapy in hemiparkinsonian monkeys.

Authors:  Susanta Mondal; Avik Roy; Arundhati Jana; Sankar Ghosh; Jeffrey H Kordower; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-03       Impact factor: 4.147

Review 3.  Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport.

Authors:  Italo Mocchetti; Alessia Bachis; Valeriya Avdoshina
Journal:  Neurotox Res       Date:  2011-09-27       Impact factor: 3.911

Review 4.  Catecholaminergic based therapies for functional recovery after TBI.

Authors:  Nicole D Osier; C Edward Dixon
Journal:  Brain Res       Date:  2015-12-19       Impact factor: 3.252

5.  Neurotrophin receptor heterozygosity causes deficits in catecholaminergic innervation of amygdala and hippocampus in aged mice.

Authors:  O von Bohlen Und Halbach; L Minichiello
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

Review 6.  Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.

Authors:  Kathryn A Frankola; Nigel H Greig; Weiming Luo; David Tweedie
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-05       Impact factor: 4.388

Review 7.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

8.  Src suppressed C kinase substrate regulates the lipopolysaccharide-induced TNF-alpha biosynthesis in rat astrocytes.

Authors:  Lin-lin Sun; Chun Cheng; Hai-ou Liu; Cong-cong Shen; Feng Xiao; Jing Qin; Jun-ling Yang; Ai-guo Shen
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

Review 9.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Altered transcription factor trafficking in oxidatively-stressed neuronal cells.

Authors:  Vivek P Patel; Donald B Defranco; Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2012-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.